Figure 1.
All patients. Event-free survival (A), overall survival (B) with estimates for 24 months after CAR T-cell infusion, relapse-free survival (C), CIR (D), NRM (E), and duration of B-cell aplasia with estimates for 24 months after response.
All patients. Event-free survival (A), overall survival (B) with estimates for 24 months after CAR T-cell infusion, relapse-free survival (C), CIR (D), NRM (E), and duration of B-cell aplasia with estimates for 24 months after response.
